{"id":49660,"date":"2022-10-14T19:01:51","date_gmt":"2022-10-14T17:01:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/"},"modified":"2022-10-14T19:01:51","modified_gmt":"2022-10-14T17:01:51","slug":"dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/","title":{"rendered":"Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels"},"content":{"rendered":"
\n

SAN FRANCISCO–(BUSINESS WIRE)–Dosis, a market leader in artificial intelligence-powered precision dosing, announced today the publication of two abstracts to be showcased at the American Society of Nephrology\u2019s (ASN) Kidney Week 2022, taking place November 3-6 in Orlando, FL. The abstracts detail the results of statistical analyses performed on clinical data drawn from Strategic Anemia Advisor (SAA), Dosis\u2019s flagship anemia management product.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nOne abstract, titled \u201cArtificial Intelligence (AI) Tool Decreases Epoetin Beta (Mircera) Drug Exposure and Maintains Hemoglobin at Desired Levels,\u201d analyzes clinical data from 2,116 patients receiving epoetin beta in 19 dialysis clinics. Mean monthly dose of epoetin beta fell 40% using SAA, from 140 micrograms per patient per month to 84 micrograms per patient per month. Patient hemoglobin averaged 10.7 grams per deciliter (g\/dL) in both the control period and in Months 5-12 during SAA use. Results are shown in Figure 1. The full abstract can be accessed here<\/a>.\n<\/p>\n

\nThe other abstract, titled \u201cDiscontinuation of Artificial Intelligence (AI) Tool for Anemia Management Results in Higher Drug Exposure, Lower Hemoglobin,\u201d presents clinical data across a 3-year period from 855 patients receiving epoetin beta in 5 dialysis clinics located in the same geographic area. The analysis demonstrates a 50-66% reduction in mean monthly epoetin beta dosage in clinics that used SAA for dosing recommendations, compared to those that did not use SAA or discontinued SAA use during the analyzed period.\n<\/p>\n

\nSAA use was left to the discretion of each clinic\u2019s medical director. Two clinics used SAA over the full duration of the analyzed period, one clinic did not use SAA at all during the analyzed period, and the remaining two clinics discontinued use of SAA during the analyzed period. The two clinics that used SAA for the entire analyzed period had higher hemoglobin levels and 50-66% lower monthly doses of epoetin beta per patient than the clinic that did not use SAA at all. The two clinics that discontinued SAA use during the analyzed period saw hemoglobin levels fall by 0.6 g\/dL and monthly epoetin beta dose per patient rise by 50-57%. Results are shown in Figure 2. The full abstract can be accessed here<\/a>.\n<\/p>\n

\n\u201cKidney Week 2022 provides us with a unique opportunity to share the irreplaceable value our products deliver to the nephrology community,\u201d said Shivrat Chhabra, Chief Executive Officer and co-founder of Dosis. \u201cRising costs in the current macroeconomic environment and the shift to value-based care are driving the need for precision medicine tools that maximize patient outcomes while reducing the cost of care. We offer kidney care providers the tools they need to get a step ahead of the competition in this shifting marketplace.\u201d\n<\/p>\n

\nSAA calculates and delivers a personalized dosing recommendation for each patient based on the patient\u2019s past Erythropoiesis Stimulating Agent (ESA) doses, hemoglobin levels, and target hemoglobin range, helping manage their hemoglobin levels while reducing unnecessary ESA exposure and drug cost. SAA\u2019s personalized dosing recommendations represent a generational leap in dosing efficiency when compared to conventional one-size-fits-all dosing approaches.\n<\/p>\n

\n\u201cWe are proud to present these results and believe they will drive continued adoption of AI-driven personalized dosing tools by the dialysis industry,\u201d said Chhabra, with Dosis\u2019s momentum continuing to accelerate after its announcement earlier this year of a nationwide implementation of SAA with a major U.S. dialysis provider<\/a>.\n<\/p>\n

\nAbout Dosis Inc.<\/b>\n<\/p>\n

\nDosis Inc. is a San Francisco-based precision medicine software company on a mission to transform chronic disease management by leveraging advancements in artificial intelligence and control algorithms. With a deep academic foundation, Dosis uses science, data, patient safety, and clinical evidence to create precision dosing tools for health care providers. For more information about the technology behind SAA, visit dosisinc.com\/platform<\/a>, and for more information about Dosis, visit dosisinc.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nDosis Media Team
\n
hello@dosisinc.com<\/a>
353 Sacramento Street, Ste 1800
\n
San Francisco, CA 94111\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO–(BUSINESS WIRE)–Dosis, a market leader in artificial intelligence-powered precision dosing, announced today the publication of two abstracts to be showcased at the American Society of Nephrology\u2019s (ASN) Kidney Week 2022, taking place November 3-6 in Orlando, FL. The abstracts detail the results of statistical analyses performed on clinical data drawn from Strategic Anemia Advisor … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49660","6":"format-standard","7":"category-industry"},"yoast_head":"\nDosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO–(BUSINESS WIRE)–Dosis, a market leader in artificial intelligence-powered precision dosing, announced today the publication of two abstracts to be showcased at the American Society of Nephrology\u2019s (ASN) Kidney Week 2022, taking place November 3-6 in Orlando, FL. The abstracts detail the results of statistical analyses performed on clinical data drawn from Strategic Anemia Advisor ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-14T17:01:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221014005354\/en\/1602563\/21\/D_Figure_1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels\",\"datePublished\":\"2022-10-14T17:01:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/\"},\"wordCount\":640,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005354\\\/en\\\/1602563\\\/21\\\/D_Figure_1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/\",\"name\":\"Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005354\\\/en\\\/1602563\\\/21\\\/D_Figure_1.jpg\",\"datePublished\":\"2022-10-14T17:01:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005354\\\/en\\\/1602563\\\/21\\\/D_Figure_1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221014005354\\\/en\\\/1602563\\\/21\\\/D_Figure_1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/","og_locale":"en_US","og_type":"article","og_title":"Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels - Pharma Trend","og_description":"SAN FRANCISCO–(BUSINESS WIRE)–Dosis, a market leader in artificial intelligence-powered precision dosing, announced today the publication of two abstracts to be showcased at the American Society of Nephrology\u2019s (ASN) Kidney Week 2022, taking place November 3-6 in Orlando, FL. The abstracts detail the results of statistical analyses performed on clinical data drawn from Strategic Anemia Advisor ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-14T17:01:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221014005354\/en\/1602563\/21\/D_Figure_1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels","datePublished":"2022-10-14T17:01:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/"},"wordCount":640,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221014005354\/en\/1602563\/21\/D_Figure_1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/","url":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/","name":"Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221014005354\/en\/1602563\/21\/D_Figure_1.jpg","datePublished":"2022-10-14T17:01:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221014005354\/en\/1602563\/21\/D_Figure_1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221014005354\/en\/1602563\/21\/D_Figure_1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/dosis-demonstrates-40-reduction-in-epoetin-beta-utilization-with-maintained-hemoglobin-levels\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Dosis Demonstrates 40% Reduction in Epoetin Beta Utilization with Maintained Hemoglobin Levels"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49660"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49660\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}